Ding Xiaoling, Sun Xinchen, Cai Huihui, Wu Lei, Liu Ying, Zhao Yu, Zhou Dingjingyu, Yu Guiping, Zhou Xiaorong
Department of Immunology, Nantong University, School of Medicine, Nantong, China.
Department of Gastroenterology, The Affiliated Hospital of Nantong University, Nantong, China.
Front Oncol. 2022 Jan 6;11:786913. doi: 10.3389/fonc.2021.786913. eCollection 2021.
Macrophages play critical roles in tumor progression. In the tumor microenvironment, macrophages display highly diverse phenotypes and may perform antitumorigenic or protumorigenic functions in a context-dependent manner. Recent studies have shown that macrophages can be engineered to transport drug nanoparticles (NPs) to tumor sites in a targeted manner, thereby exerting significant anticancer effects. In addition, macrophages engineered to express chimeric antigen receptors (CARs) were shown to actively migrate to tumor sites and eliminate tumor cells through phagocytosis. Importantly, after reaching tumor sites, these engineered macrophages can significantly change the otherwise immune-suppressive tumor microenvironment and thereby enhance T cell-mediated anticancer immune responses. In this review, we first introduce the multifaceted activities of macrophages and the principles of nanotechnology in cancer therapy and then elaborate on macrophage engineering nanotechnology or genetic approaches and discuss the effects, mechanisms, and limitations of such engineered macrophages, with a focus on using live macrophages as carriers to actively deliver NP drugs to tumor sites. Several new directions in macrophage engineering are reviewed, such as transporting NP drugs through macrophage cell membranes or extracellular vesicles, reprogramming tumor-associated macrophages (TAMs) by nanotechnology, and engineering macrophages with CARs. Finally, we discuss the possibility of combining engineered macrophages and other treatments to improve outcomes in cancer therapy.
巨噬细胞在肿瘤进展中发挥着关键作用。在肿瘤微环境中,巨噬细胞表现出高度多样的表型,并可能根据具体情况发挥抗肿瘤或促肿瘤功能。最近的研究表明,可以对巨噬细胞进行改造,使其以靶向方式将药物纳米颗粒(NPs)转运至肿瘤部位,从而发挥显著的抗癌作用。此外,经改造表达嵌合抗原受体(CARs)的巨噬细胞被证明能主动迁移至肿瘤部位,并通过吞噬作用清除肿瘤细胞。重要的是,到达肿瘤部位后,这些经过改造的巨噬细胞可显著改变原本具有免疫抑制作用的肿瘤微环境,从而增强T细胞介导的抗癌免疫反应。在这篇综述中,我们首先介绍巨噬细胞的多方面活动以及纳米技术在癌症治疗中的原理,然后详细阐述巨噬细胞工程——纳米技术或基因方法,并讨论此类经改造巨噬细胞的作用、机制和局限性,重点是利用活巨噬细胞作为载体将NP药物主动递送至肿瘤部位。本文综述了巨噬细胞工程的几个新方向,如通过巨噬细胞膜或细胞外囊泡转运NP药物、利用纳米技术对肿瘤相关巨噬细胞(TAMs)进行重编程以及用CARs改造巨噬细胞。最后,我们讨论了将经改造的巨噬细胞与其他治疗方法相结合以改善癌症治疗效果的可能性。